These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25670381)

  • 1. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs.
    Kesselheim AS; Tan YT; Darrow JJ; Avorn J
    Health Aff (Millwood); 2014 Oct; 33(10):1770-8. PubMed ID: 25288421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Drugs Approved in 2019.
    Ebied AM; Patel KH; Cooper-DeHoff RM
    Am J Med; 2020 Jun; 133(6):675-678. PubMed ID: 32145207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development in serious diseases: the new "breakthrough therapy" designation.
    Woodcock J
    Clin Pharmacol Ther; 2014 May; 95(5):483-5. PubMed ID: 24747238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A drug's life: the pathway to drug approval.
    Keng MK; Wenzell CM; Sekeres MA
    Clin Adv Hematol Oncol; 2013 Oct; 11(10):646-55. PubMed ID: 24518374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversy still swirls around FDA user fees: since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals--but does speed equal safety?
    Ullman K
    Ann Neurol; 2013 Nov; 74(5):A10-1. PubMed ID: 24353218
    [No Abstract]   [Full Text] [Related]  

  • 16. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expediting drug development--the FDA's new "breakthrough therapy" designation.
    Sherman RE; Li J; Shapley S; Robb M; Woodcock J
    N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.